About ReBEC

The Brazilian Clinical Trials Registry (ReBEC) is an open-access virtual platform for registering experimental and non-experimental studies involving human beings conducted in Brazilian territory by Brazilian and foreign researchers. ReBEC is a joint project of the Ministry of Health (DECIT/MS), the Pan American Health Organization (PAHO), and the Oswaldo Cruz Foundation (FIOCRUZ). The Executive Committee of ReBEC is composed of the aforementioned institutions and the National Health Surveillance Agency (ANVISA). ReBEC is an important source of information for patients, healthcare professionals, researchers, companies, and research centers. Its support services feature generative artificial intelligence ReBEC@, the first artificial intelligence for clinical trial registration in the world. Learn more

Everything you need to know about ReBEC

Click to access the hotsite

Click to download the PDF version

Instructions for the Registrant

We recommend reading the Registrant's Manual.

1 - Register or log in and fill out the forms normally in Portuguese and English.
For English, if you experience any difficulty, use Google Translate
(or another free translation tool).
2 - Attach the mandatory ethics committee documentation and submit the form.
3 - Save the support number in your WhatsApp contacts. Send a message with your name and username.
It is not necessary or recommended to send your password. 
4 - A reviewer will respond to you. Choose your preferred communication mode:
chat, audio recordings, or scheduled voice call.
5 - Your form will be reviewed in both languages. Follow further instructions to complete approval.

Clinical Research Volunteer

Would you like to become a volunteer in a clinical trial registered in ReBEC?

Access our FAQ to find out how.

11/05/2026 | Ministério da Ciência, Tecnologia e Inovação

https://www.gov.br/mcti/pt-br/acompanhe-o-mcti/noticias/2026/11/pesquisas-do-cnpem-investigam-metastase-e-resposta-do-cancer-de-mama-a-tratamentos 

Studies using patient-derived cells, nanoparticles, and new technologies aim to understand the differences between tumors and contribute to more personalized treatments.

Why might patients with seemingly similar tumors respond differently to the same medications? How do breast cancer cells manage to reach the brain?

Researchers at the Brazilian Center for Research in Energy and Materials (CNPEM), in Campinas (São Paulo state), are investigating these questions through various approaches, seeking to expand knowledge about the disease and identify factors that influence treatment response.

The research focuses on the mechanisms of cancer and the identification of factors that affect how it responds to treatment. To this end, the team employs three-dimensional models cultured from patient samples, as well as nanoparticles and devices that integrate sensors with artificial intelligence techniques.

“Our research at CNPEM seeks to understand why breast tumors respond differently to treatments and how certain cells manage to spread to other organs,” explains researcher Sandra Dias.

How do cancer cells spread throughout the body?

Part of this research tracks cells that detach from the original tumor and enter the bloodstream. Some of these cells survive and reach other organs, contributing to the spread of the disease—a process known as metastasis.

Cyro Negrão is studying a strategy that uses nanoparticles to bring these circulating tumor cells into closer proximity with…

11/05/2026 | Gabriela Costa | Portal Afya

https://portal.afya.com.br/saude/oms-inclui-duas-novas-vacinas-contra-ebola-em-ensaio-clinico 

The World Health Organization (WHO) is expanding research into Ebola vaccines and investigating new therapies, with clinical results expected in the coming months.

On November 4, the World Health Organization (WHO) recommended the inclusion of two Ebola vaccine candidates in the "Tumaini" clinical trial in the Democratic Republic of the Congo. These vaccines were developed specifically to target the Bundibugyo virus—the strain responsible for the outbreak in the country—and will be incorporated into the study following national regulatory approvals.

The recommendation was made by independent experts convened by the WHO, following an analysis of preclinical evidence and initial clinical data. The investigation aims to determine the efficacy of these candidates during an active outbreak—a crucial step in establishing their potential to provide protection.

Tumaini clinical trial employs ring vaccination
The vaccines selected for evaluation are ChAdOx1, developed by the University of Oxford in partnership with the Serum Institute of India, and mRNA-1469, developed by Moderna. The Tumaini trial allows for the investigation of multiple vaccine candidates under a single protocol, utilizing a "ring vaccination" strategy among the contacts of individuals with a confirmed Bundibugyo infection.

The vaccine Ervebo is also being evaluated in the trial to determine its efficacy against the Bundibugyo strain. While its effectiveness against the Zaire species of the Ebola virus has already been established, this does not confirm protection against the specific strain involved in the current outbreak.

Four "vaccination…

11/05/2026 | Jair Onofre | Bahia na Politica

https://bahianapolitica.com.br/ministerio-da-saude-divulga-edital-que-cria-cadastro-nacional-de-centros-de-pesquisa-clinica/ 

Where are clinical research centers located in Brazil, and what are their areas of focus, staffing, and equipment? To answer these questions, the Ministry of Health published a call for registration in the *Diário Oficial da União* (Official Gazette) this Tuesday (3rd), establishing the National Registry of Clinical Research Centers (CNCPC).

The goal is to create an official, standardized, and detailed database containing information on public and private centers from all regions of the country—regardless of their affiliations or participation in studies sponsored by companies, industries, or funding institutions. In addition to hospitals, universities, institutes, clinics, and healthcare units, other entities that conduct such research—even without a dedicated, exclusive structure for the activity—may also participate. This includes, for example, specialized outpatient clinics, diagnostic services, and clinical analysis laboratories, provided they meet the requirements set forth in the public notice.

Managed by the Secretariat for Science, Technology, and Innovation in Health (SCTIE), the registration form was developed with input from the scientific community. It aims to gather data that will help identify existing strengths, address needs for professional qualification, increase transparency regarding clinical research capacity, and reduce regional disparities.

According to Fernanda De Negri, Secretary of the SCTIE, this mapping effort will support the consolidation of existing public policies aimed at developing clinical research that serves the Brazilian population. “In practice,…

11/04/2026 | Bruno Lauterjung | Digital Health News

https://saudedigitalnews.com.br/04/11/2026/oracle-aposta-em-inteligencia-artificial-para-reduzir-barreiras-no-atendimento-e-na-pesquisa-medica/ 

Artificial intelligence can transform the way hospitals, laboratories, and healthcare professionals share information, monitor patients, and develop treatments. That was the main message from Larry Ellison, founder and CTO of Oracle, during Oracle AI World 2026, held last week in Las Vegas, United States. The executive presented a new generation of applications for the healthcare sector, designed to integrate clinical and administrative processes with AI capabilities.

Under the theme “The New Oracle Health Application Suite and the Age of AI,” Ellison outlined the company’s strategy to expand the reach of Oracle Health. The goal is to build a platform capable of connecting hospitals, clinics, laboratories, diagnostic imaging centers, emergency services, and home care, thereby reducing the fragmentation of the systems used by these institutions.

According to the executive, Oracle chose healthcare as the starting point for developing industry-specific applications based on artificial intelligence because it considers this one of the most complex markets in the world. In addition to the diversity of medical specialties, the sector must keep pace with scientific advancements and meet regulatory requirements that vary from country to country.

One of the key proposed changes involves how professionals interact with hospital systems. Instead of navigating through different screens to locate test results, review medical records, or enter information, doctors will be able to use natural language commands to access data and perform specific tasks.

Ellison illustrated…

11/04/2026 | WHO

https://www.who.int/news/item/04-11-2026-two-new-candidate-vaccines-to-join-ebola-trial-as-treatment-research-advances 

Expert groups convened by the World Health Organization (WHO) have recommended adding two new Ebola vaccine candidates to the ongoing Tumaini clinical trial in the Democratic Republic of the Congo (DRC). The recommendation marks the first time vaccines specifically designed to protect against Bundibugyo virus, the virus responsible for the current outbreak, will be evaluated during an outbreak of the disease.

The two vaccine candidates are ChAdOx1, developed by the University of Oxford with the Serum Institute of India, and Moderna’s mRNA-1469. WHO’s independent Technical Advisory Group on Candidate Vaccines Prioritization recommended both for further clinical evaluation this week, based on available preclinical and early clinical evidence. The companies were informed on Monday. The vaccine candidates will enter the trial following national approvals.

“The fact that these vaccines are ready to enter clinical trials is a testament to the power of science and partnership,” said Dr Tedros Adhanom Ghebreyesus, WHO Director-General. “I thank the scientists, health workers and partners in the DRC and around the world who have brought us to this point, and especially the people taking part in the trial. Their participation will generate vital evidence that could help save lives. Vaccines alone will not end this outbreak, but they could become a powerful new tool for bringing it under control.”

The Institut National de Recherche Biomédicale, the DRC's national public health and biomedical research institute is leading the vaccines trial, with support from the University of Antwerp, Belgium, WHO, Epicentre, Médecins…